product
igg
respons
viru
infect
central
antivir
immun
effector
function
hallmark
b
cell
memori
antivir
antibodi
ab
recognis
viral
glycoprotein
protein
antigen
display
surfac
virion
virusinfect
cell
crucial
render
viru
noninfecti
elimin
virus
infect
cell
either
act
alon
conjunct
complement
mani
instanc
passiv
transfer
ab
suffici
protect
viral
infect
herpesvirus
hv
equip
larg
array
immunomodulatori
function
increas
effici
infect
dampen
antivir
immun
member
aand
hsubfamili
herpesvirida
distinct
encod
transmembran
glycoprotein
select
bind
igg
via
fc
domain
fcbind
protein
constitut
viral
fcg
receptor
vfcgr
express
cell
surfac
infect
cell
moreov
vfcgr
abundantli
incorpor
envelop
virion
despit
molecular
structur
heterogen
vfcgr
gener
interfer
iggmedi
effector
function
like
antibodi
ab
depend
cellular
cytolysi
complement
activ
neutralis
infect
virion
vfcgr
may
thu
contribut
limit
therapeut
potenc
antiherpesvir
igg
clinic
set
detail
molecular
understand
vfcgr
open
possibl
design
recombin
igg
molecul
resist
vfcgr
engin
igg
better
antivir
effici
repres
new
therapeut
option
herpesvir
diseas
herpesvirus
hv
subdivid
three
subfamili
h
g
possess
larg
doublestrand
dna
genom
encod
approxim
gene
hv
genom
remain
latent
natur
host
initi
product
infect
latent
infect
cell
result
viru
shed
transmiss
viru
progeni
new
host
long
histori
coevolut
cospeci
host
hv
adopt
multipl
mechan
deal
immun
function
permit
establish
lifelong
infect
effici
replic
transmiss
even
presenc
repeatedli
booster
antivir
immun
respons
typic
herpesvir
evas
strategi
promin
target
immun
respons
attack
contain
viru
highest
effici
ie
cytotox
cell
natur
killer
nk
cell
interferon
ab
hand
finetun
host
defenc
strategi
avoid
irrevers
harm
led
activ
cellular
humor
immun
tightli
control
herpesvir
infect
hierarch
also
redund
manner
date
eight
human
herpesvirus
widespread
popul
known
list
tabl
major
case
virus
caus
rel
mild
even
asymptomat
infect
immmunocompet
host
howev
intric
balanc
viral
immun
escap
host
immun
lost
uncontrol
viru
replic
lead
sever
diseas
manifest
frequent
observ
immunocompromis
patient
congenit
infect
babi
complement
system
antivir
ab
form
first
line
antivir
defenc
oper
virion
abl
attach
cellular
receptor
mediat
entri
host
cell
initi
replic
cycl
complement
system
includ
proteolyt
enzym
inflammatori
protein
cell
surfac
receptor
protein
caus
cell
death
osmot
lysi
insert
biolog
membran
therefor
primari
requir
complement
cascad
becom
initi
respons
infect
initi
random
fashion
complement
factor
opsonis
lyse
abcoat
viral
particl
virolysi
infect
cell
cytolysi
broad
rang
host
cell
express
sever
complementinhibit
protein
protect
tissu
complementmedi
lysi
inhibit
dissoci
convertas
central
amplif
complement
system
notabl
cell
surfac
express
two
complement
control
protein
ccp
strongli
enhanc
plasma
membran
hcmvinfect
cell
upregul
express
increas
capac
regul
deposit
thu
protect
cmvinfect
cell
complementmedi
lysi
select
incorpor
ccp
ie
virion
discoveri
virusencod
regul
complement
activ
rca
underscor
import
antivir
role
complement
system
ab
neutralis
viru
particl
achiev
bound
ab
block
virion
product
interact
receptor
prevent
step
entri
uncoat
combin
ab
complement
activ
classic
complement
pathway
lyse
envelop
virus
express
vfcgr
protect
hsv
virion
threat
interf
recruit
complement
arsen
immmunomodulatori
mechan
hv
restrict
protect
free
viru
particl
hvinfect
cell
protect
destruct
cytotox
effector
cell
render
refractori
antivir
cytokin
like
interferon
ensur
effici
viru
replic
recent
review
delin
bewild
multitud
sophist
mechan
defenc
strategi
great
detail
ab
neutralis
virus
usual
demonstr
vitro
bind
virusspecif
ab
lead
reduct
number
infecti
particl
mechan
lead
viru
neutralis
variabl
includ
simpl
occup
viru
surfac
steric
hindranc
product
interact
cellular
receptor
caus
virion
aggreg
thu
reduc
concentr
infecti
particl
also
complex
model
involv
cap
critic
epitop
induct
conform
chang
viral
envelop
capsid
structur
enhanc
role
ab
fc
part
direct
neutralis
explain
increas
avid
dival
ab
compar
monoval
fab
fragment
mere
size
steric
occup
viru
surfac
paramount
import
function
ab
fc
moieti
recruit
complement
system
enhanc
vivo
neutralis
induc
abdepend
complementmedi
lysi
adcl
fcreceptormedi
phagocytosi
subsequ
destruct
viru
particl
profession
antigenpres
cell
differ
abil
igg
subclass
bind
complement
therefor
explain
observ
differ
neutralis
capabl
ab
share
common
variabl
region
differ
constant
region
minor
fraction
ab
repertoir
gener
immun
respons
given
viru
neutralis
capac
addit
sever
possibl
way
ab
act
virus
nonneutralis
ab
may
promot
opsonis
phagocytosi
viru
contribut
antivir
defenc
later
stage
infect
viru
alreadi
enter
host
cell
recognit
viral
antigen
surfac
infect
cell
ab
trigger
virusspecif
kill
nonspecif
cytotox
effector
cell
carri
fc
receptor
eg
nk
cell
process
call
abdepend
cellular
cytotox
adcc
ab
coat
virusinfect
target
cell
attach
effector
cell
via
fcgr
therebi
stimul
releas
perforin
granzym
cytolyt
granula
destroy
virusinfect
cell
moreov
ab
also
block
releas
progeni
viru
infect
cell
shown
prevent
celltocel
spread
virus
multimer
iga
igm
molecul
transcytos
epitheli
cell
intrigu
function
even
beyond
igg
ig
encount
viral
antigen
insid
cell
neutralis
viru
infect
even
intracellular
site
ab
power
defenc
weapon
mani
virus
potenc
appear
restrict
hv
hv
commonli
abl
reactiv
product
infect
latenc
reach
horizont
transmiss
spread
presenc
virusspecif
ab
likewis
preexist
cmvspecif
ab
frequent
fail
prevent
viru
transmiss
exogen
superinfect
new
viru
strain
mous
model
hv
infect
mous
cmv
mcmv
murin
gherpesviru
ab
demonstr
dispens
clearanc
primari
infect
becom
limit
factor
later
prevent
dissemin
recurr
viru
postprimari
phase
infect
therapeut
effect
hyperimmun
sera
hv
limit
valu
prevent
rather
treatment
purpos
certain
clinic
set
discuss
clinic
use
antiherpesvir
igg
concentr
aand
hhv
express
fcgr
see
section
congenit
infect
newborn
hcmv
infect
import
caus
hear
loss
well
cognit
motor
impair
effect
prevent
treat
current
medic
intervent
review
ref
immun
hcmv
strongli
reduc
sever
diseas
substanti
need
vaccin
addit
hcmv
infect
major
caus
diseas
death
immunocompromis
patient
eg
solid
organ
bone
marrow
transplant
bmt
recipi
cancer
patient
hivinfect
individu
pneumonia
retin
lesion
gastrointestin
tract
common
manifest
hcmv
diseas
applic
highli
effici
anticytomegalovir
agent
like
ganciclovir
foscarnet
often
limit
due
toxic
drug
develop
drugresist
hcmv
therefor
treatment
ab
frequent
demand
option
addit
replac
therapi
standard
formul
intraven
infus
either
immunoglobulin
pool
normal
human
plasma
intraven
ig
ivig
donor
screen
high
anticmv
titer
cmvigiv
cmvigiv
distribut
trade
name
cytogamr
cytotectr
indic
prophylaxi
cmv
diseas
associ
transplant
kidney
lung
liver
pancrea
heart
latest
therapeut
regimen
includ
combin
antivir
like
gancyclovir
cmvigiv
increas
clinic
benefit
therapeut
valu
cmvigiv
extens
studi
review
overal
studi
abl
demonstr
moder
reduct
cmvassoci
morbid
defin
transplant
set
due
limit
efficaci
polyclon
cmvigiv
igg
defin
reactiv
hcmv
antigen
develop
immunodomin
cmv
envelop
glycoprotein
gb
gh
carri
neutralis
b
cell
epitop
involv
viru
attach
fusion
host
cell
celltocel
spread
intern
virion
therefor
gb
gh
obviou
candid
target
ab
gener
human
monoclon
antighab
sevirumabr
neutralis
capac
fail
exert
benefici
effect
cmvseroposit
hematopoiet
stem
cell
transplant
hsct
recipi
similarli
antihcmv
ab
includ
humanis
mous
monoclon
igg
capabl
neutralis
hcmv
vitro
proven
effect
therapeut
applic
vivo
sever
approach
use
attenu
live
viru
viral
subunit
like
gb
undertaken
produc
hcmv
vaccin
abl
gener
gbspecif
ab
demonstr
neutralis
capac
howev
effici
hcmv
vaccin
avail
clinic
purpos
far
share
abil
establish
latent
infect
sensori
neuron
accomplish
recurr
cycl
reactiv
frequent
lead
pain
labial
genit
lesion
respect
immunosuppress
increas
risk
sever
hsv
diseas
cutan
dissemin
infect
central
nervou
system
sever
line
circumstanti
evid
suggest
protect
effect
igg
first
risk
viru
transmiss
extent
neonat
diseas
much
lower
mother
recurr
compar
primari
genit
infect
second
mous
model
infect
variou
vaccin
protocol
gener
ab
respons
mediat
partial
vagin
immun
recent
effort
vaccin
gener
employ
glycoproteind
gd
subunit
formul
sinc
gd
target
neutralis
ab
due
fact
gd
directli
interact
hsv
receptor
cell
surfac
trigger
viru
entri
two
phase
studi
glaxosmithklin
gdsubunit
vaccin
demonstr
efficaci
prevent
occurr
genit
herp
diseas
women
seroneg
vaccin
complet
ineffect
decreas
infect
men
women
seroposit
similarli
chiron
vaccin
use
similar
protein
compon
administ
differ
adjuv
ineffect
prevent
infect
vzv
common
etiolog
agent
two
diseas
varicella
ie
primari
vzv
infect
chickenpox
zoster
ie
shingl
result
local
reactiv
infect
endogen
vzv
genom
dorsal
root
ganglia
cell
immunocompet
children
varicella
usual
benign
selflimit
diseas
gener
treatment
requir
contrast
nonimmun
patient
belong
highrisk
group
like
immunocompromis
individu
exposur
vzv
newborn
whose
mother
undergo
varicella
deliveri
must
receiv
vzv
immunoglobulin
vzig
situat
varicella
take
lifethreaten
cours
infect
vzig
clearli
effici
postexposur
prophylaxi
benefici
therapi
alreadi
establish
vzv
infect
herp
zoster
occur
presenc
vzvspecif
ab
accordingli
vzig
prevent
therapeut
effect
herp
zoster
underlin
resili
hv
igg
contrast
hcmv
hsv
activ
immunis
vzv
success
accomplish
live
attenu
viru
use
approv
unit
state
sinc
vzv
vaccin
protect
sever
varicella
although
superinfect
vaccine
exogen
wildtyp
vzv
strain
reactiv
vaccin
viru
may
occur
earli
vaccin
studi
children
leukemia
suggest
incid
zoster
might
lower
patient
receiv
attenu
oka
vaccin
strain
infect
wildtyp
viru
present
clear
whether
vaccin
reduc
overal
incid
zoster
healthi
vaccin
individu
taken
togeth
antiherpesvir
igg
certain
limit
prophylact
rather
therapeut
effect
control
hv
spread
progress
sever
diseas
ab
alon
howev
fail
provid
steril
protect
immun
specif
surfaceexpress
cellular
receptor
known
ig
class
includ
iga
fcar
igd
fcyr
ige
fcqr
igg
fcgr
igm
fcar
ig
receptor
exert
essenti
function
distribut
ab
like
polymer
ig
receptor
transport
iga
igm
across
epithelia
neonat
fcr
fcrn
deliv
matern
igg
foetu
across
placenta
recent
new
famili
consist
sever
member
bcellexpress
fcr
homolog
discov
precis
function
remain
elucid
class
cellular
fcr
belong
immunoglobulin
supergen
famili
igsf
cell
surfac
molecul
igsf
domain
characteris
conserv
structur
motif
term
immunoglobulin
fold
review
ref
consist
two
layer
antiparallel
hsheet
connect
variabl
loop
ig
domain
autonom
fold
unit
manifold
occurr
variou
kind
protein
best
studi
prototyp
fcr
iggbind
fcgri
fcgrii
fcgriii
exclus
express
immun
cell
act
interfac
humor
cellular
immun
fcgri
transmembran
protein
three
extracellular
ig
domain
class
ig
domain
see
fig
bind
human
iggfc
high
affin
third
juxtamembran
domain
respons
high
affin
bind
first
two
domain
alon
mediat
weak
bind
igg
fcgri
fcg
receptor
strongli
bind
monomer
igg
molecul
signal
unless
igg
crosslink
specif
polymer
ligand
fcgrii
fcgriii
preferenti
bind
polymer
monomer
igg
possess
two
extracellular
ig
domain
exhibit
closest
similar
membran
distal
domain
fcgri
fcgrii
isoform
b
transmembran
protein
differ
cytoplasm
portion
fcgriii
express
transmembran
gpilink
form
fig
cellular
fcgr
use
distinct
intracytoplasm
motif
signal
transduct
cell
fcgriia
fcgriib
contain
immunoreceptortyrosinebas
activ
motif
itam
immunoreceptortyrosinebas
inhibitori
motif
itim
respect
cytoplasm
tail
motif
phosphoryl
upon
receptor
engag
oppos
outcom
itam
preferenti
recruit
srcfamili
tyrosin
kinas
induc
cellular
activ
itim
phosphoryl
serv
termin
signal
mostli
via
inositol
phosphatas
ship
fcgri
fcgriii
contain
intrins
signal
properti
share
common
fcr
g
chain
altern
fcgriii
utilis
close
relatedchain
tcellreceptor
complex
fcr
g
thechain
contain
itam
motif
induc
activatori
signal
event
like
fcgriia
cytoplasm
moieti
crosslink
fcgribound
igg
multival
antigen
bind
preform
immun
complex
fcgrii
fcgriii
result
cluster
fcgr
r
trigger
varieti
effector
mechan
adcc
phagocytosi
releas
cytokin
enhanc
antigen
present
regul
ig
product
b
cell
thu
cfcgr
function
consid
antigen
receptor
fc
portion
ig
form
wellcharacteris
structur
bind
cfcr
mediat
membraneproxim
second
igsf
domain
cfcr
reveal
recent
studi
resolv
crystal
structur
fcgriii
complex
iggfc
fcgriia
complex
iggfc
fcqri
bound
igefc
studi
reveal
conserv
arrang
two
ig
domain
highli
bent
conform
uncov
ig
bind
site
locat
top
second
ig
domain
concordantli
three
molecul
interestingli
three
fcgr
also
occur
solubl
form
serum
gener
either
proteolysi
altern
splice
separ
gene
function
signific
isoform
remain
unravel
studi
take
advantag
gene
knockout
mice
demonstr
promin
immunoregulatori
properti
cfcgr
mice
devoid
common
fcr
g
chain
display
pleiotrop
defect
immun
effector
cell
includ
impair
macrophag
phagocytosi
nkcellmedi
adcc
well
defect
mast
celldepend
allerg
respons
similar
phenotyp
fcgriiidefici
mice
illustr
intim
function
cooper
g
chain
critic
regulatori
inhibitori
effect
fcgriib
variou
immun
cell
reflect
hyperreact
immun
system
fcgriibdefici
anim
due
lack
control
b
cell
prolifer
fcgriibdefici
mice
develop
variou
form
autoimmun
diseas
either
spontan
experiment
induct
mast
cell
fcgriibdefici
anim
hypersensit
igginduc
degranul
culmin
enhanc
passiv
cutan
analphylaxi
reaction
cellular
fcgr
play
key
role
transduc
antivir
potenc
specif
igg
cellular
immun
variou
pathogen
exploit
principl
bind
igg
fc
proport
purpos
avoid
immun
destruct
exampl
fcbind
protein
found
gramposit
bacteria
protozoa
like
schistosom
trypanosom
coronavirus
hepat
c
viru
commonli
aand
hherpesvirus
last
group
compris
cytomegalovirus
differ
speci
herp
simplex
virus
varicella
zoster
viru
vzv
porcin
herpesviru
pseudorabi
viru
prv
presum
also
marek
diseas
viru
mdv
aherpesviru
infect
chicken
protein
homolog
aherpesviru
fcgr
found
abil
cell
bind
human
igg
via
fcpart
first
demonstr
respons
membran
protein
subsequ
identifi
complex
form
glycoprotein
ge
gi
fig
encod
hsv
gene
us
uniqu
short
dispens
hsv
infect
replic
vitro
homolog
molecul
ge
gi
found
vzv
prv
mdv
ge
gi
expos
surfac
infect
cell
repres
also
abund
structur
glycoprotein
within
viru
envelop
align
limit
portion
extracellular
chain
ge
reveal
low
sequenc
similar
second
domain
cfcgr
ge
alon
bind
aggreg
igg
low
affin
complex
format
gi
induc
high
affin
receptor
abl
fix
monomer
igg
ge
gi
complex
heterodim
compos
one
molecul
bind
igg
stoichiometri
affin
igg
highest
k
nm
ge
gi
complex
bind
igg
second
third
ig
domain
interfac
similar
fcbind
site
rheumatoid
factor
protein
staphylococcu
aureu
import
interact
correl
failur
bind
mani
subclass
allotyp
correspond
residu
arginin
iggbind
capabl
ge
gi
protect
hsvinfect
cell
adcc
mice
passiv
immunis
human
antihsvigg
titer
ge
mutant
insert
disrupt
region
homolog
mammalian
fcgr
significantli
reduc
wherea
wildtyp
hsv
remain
unaffect
minim
mutat
introduc
ge
mutant
affect
iggrel
function
ge
gi
interfer
import
ge
function
ie
mediat
direct
celltocel
spread
nascent
virion
observ
protect
antivir
igg
confer
ge
gi
explain
antibodi
bipolar
bridg
abb
fig
accord
model
igg
molecul
recognis
epitop
surfac
virusinfect
cell
virion
via
clonotyp
antigen
bind
fab
domain
simultan
sequest
ge
gi
complex
via
fc
part
thu
igg
fc
domain
prevent
recruit
effector
mechan
ie
complement
compon
fcgrexpress
cytotox
effector
cell
sever
line
evid
support
hypothesi
first
competit
bind
site
ge
gi
protein
fc
interfac
exploit
demonstr
mask
fc
part
igg
viral
fcgr
bound
hsvinfect
cell
via
antigenbind
site
second
fluoresc
reson
energi
transfer
fret
studi
demonstr
igg
molecul
structur
inde
equip
suffici
intrins
flexibl
allow
simultan
interact
fab
fc
domain
separ
ligand
display
cell
virion
surfac
vzv
ge
vfcgr
demonstr
undergo
repeat
cycl
receptormedi
endocytosi
recycl
plasma
membran
vzvinfect
cell
function
depend
tyrosin
residu
conserv
yxxl
motif
resembl
endocytosi
signal
interestingli
process
induc
fc
bind
ge
find
suggest
vfcgr
might
design
molecular
devic
remov
antivir
igg
surfac
infect
cell
thu
avoid
adcc
adcl
biochem
evid
hcmvinduc
fcbind
activ
infect
fibroblast
collect
almost
three
decad
igg
bind
detect
plasma
membran
intracellular
site
infect
cell
well
associ
hcmv
virion
fc
bind
ascrib
variou
protein
mw
kda
recent
three
viral
gene
encod
two
differ
fc
bind
glycoprotein
identifi
within
hcmv
genom
dispens
viral
replic
vitro
equip
two
distinct
fcgr
uniqu
hcmv
add
anoth
exampl
bewild
array
hcmv
glycoprotein
hv
modul
immun
function
structur
composit
hcmvencod
vfcgr
thoroughli
differ
hsv
ge
gi
heterodim
former
repres
singlechain
type
transmembran
protein
show
signific
sequenc
homolog
human
cfcgr
extralumin
part
predict
form
igsflik
domain
fig
express
earli
late
phase
hcmv
infect
hitherto
unidentifi
splice
kb
transcript
encompass
open
read
frame
complex
transcript
unit
gene
sequenc
encod
type
ia
transmembran
protein
potenti
nglycosyl
site
extracellular
domain
predict
contain
singl
vlike
immunoglobulin
superfamili
igsf
domain
aa
includ
conserv
disulphid
bond
comparison
cellular
fcgr
domain
display
highest
degre
homolog
uniqu
third
igsf
domain
fcgri
domain
confer
high
affin
bind
igg
secondari
structur
algorithm
concordantli
predict
composit
igsf
domain
built
seven
hsheet
resembl
architectur
cfcgr
igsf
domain
cytoplasm
domain
contain
modifi
itim
motif
wsykrl
may
provid
link
cellular
signal
pathway
glycoprotein
encod
two
ident
gene
copi
latter
present
duplic
uniqu
long
segment
laboratori
hcmv
strain
type
ia
transmembran
protein
consist
aa
extracellular
region
includ
three
potenti
nglycosyl
site
predict
form
one
igsflik
domain
predict
base
homolog
second
domain
cfcgriiirii
form
essenti
igg
bind
moieti
cfcgr
import
determin
three
cfcgriii
bind
region
fc
fragment
conserv
sequenc
interestingli
secondari
structur
calcul
predict
ahel
interrupt
hsheet
structur
igsf
domain
featur
resembl
fcrn
ahelic
also
make
import
fig
herpesvir
fcgr
protect
antivir
igg
antibodybipolar
bridg
antivir
igg
bind
cognat
viral
antigen
surfac
infect
cell
viru
particl
via
fab
part
upon
bind
fc
region
recruit
r
complex
activ
complement
system
via
classic
pathway
result
antibodydepend
complementmedi
lysi
adcl
b
altern
attach
bound
virusspecif
igg
cfcgr
cytotox
effector
cell
eg
nk
cell
mediat
cfcgr
crosslink
trigger
antibodydepend
cellular
cytotox
adcc
c
antibodybipolar
bridg
viral
fcgr
sequest
fc
part
bound
antivir
igg
engag
block
recruit
complement
protein
cfcgr
thu
mediat
protect
viru
particl
infect
cell
destruct
contribut
bind
interfac
higg
cytoplasm
tail
contain
conserv
dileucin
motif
dxxxll
could
indic
role
intracellular
target
igg
complex
endocyt
rout
thu
similar
vzv
ge
gi
hcmv
might
remov
bound
igg
plasma
membran
infect
cell
prevent
adcl
adcc
contrast
hsv
ge
gi
fcgr
hcmvinfect
cell
shown
bind
subclass
human
igg
graduat
affin
z
howev
experiment
set
use
could
dissolv
separ
ig
bind
properti
like
exist
given
differ
affin
igg
distinct
mammalian
speci
among
nonhuman
igg
rabbit
minor
extent
rat
igg
recognis
bind
observ
ultrastructur
inform
reveal
exact
bind
contact
site
hcmv
fcgr
fc
ligand
avail
yet
howev
one
conclus
regard
fc
molecul
drawn
form
fact
fcbound
vfcgr
still
precipit
protein
impli
separ
bind
site
must
exist
featur
hcmv
fcgr
contrari
hsv
ge
gi
aureu
protein
compet
fc
bind
similar
hsv
ge
gi
hcmv
fcgr
independ
interf
neutralis
function
human
igg
reinhard
h
hengel
h
unpublish
observ
fact
also
evid
plaqu
reduct
assay
hcmvimmun
human
sera
perform
presenc
excess
fc
fragment
h
control
protein
addit
fc
h
improv
neutralis
effici
hcmvigg
dosedepend
manner
activ
measl
viru
mv
specif
igg
complet
independ
fc
neutralis
mv
virion
possess
vfcgr
reinhard
h
hengel
h
unpublish
observ
find
may
obviou
implic
invivo
neutralis
hcmv
bodi
fluid
like
blood
high
amount
nonimmun
igg
might
exert
similar
effect
like
fc
fragment
neutralis
assay
discuss
ie
enhanc
hcmv
virion
neutralis
contrast
site
igg
concentr
significantli
lower
serum
ie
mucos
surfac
bodi
fluid
like
saliva
breast
milk
genit
fluid
hcmv
vfcgr
promot
viru
shed
horizont
transmiss
environ
vfcgr
critic
requir
confer
resist
hcmv
particl
neutralis
igg
notabl
hcmv
vfcgr
could
also
provid
molecular
link
infect
replic
human
immunodefici
viru
hiv
hivinduc
damag
host
immun
system
favour
hcmv
reactiv
latenc
emerg
persist
hcmv
replic
recurr
diseas
context
interest
hcmv
infect
abl
confer
hivsuscept
otherwis
nonpermiss
fibroblast
could
explain
abcoat
hiv
particl
attach
via
vfcgr
surfac
hcmvinfect
cell
mechan
hiv
virion
might
endocytos
establish
hiv
infect
could
open
cellular
compart
hiv
replic
hiv
may
benefit
multitud
stealth
mechan
hcmv
avoid
immun
attack
mous
cmv
mcmv
infect
cell
decor
iggfc
fragment
intracellularli
surfac
genet
basi
featur
express
singl
gene
code
fcgr
predict
type
transmembran
glycoprotein
calcul
mass
kda
synthesis
earli
late
phase
mcmv
replic
mcmv
fcgr
highli
glycosyl
reach
mw
kda
reduc
singl
band
kda
deglycosyl
protein
precipit
mous
iggfc
fragment
coupl
protein
indic
nonoverlap
bind
site
case
hcmv
fcgr
align
sequenc
mous
cfcgr
display
signific
degre
homolog
predict
composit
three
fcgrrelat
igsflik
domain
fig
zimmermann
bigl
h
hengel
unpublish
data
two
distinct
independ
homolog
present
two
differ
cytomegalovirus
rat
rcmv
rcmv
strain
maastricht
rcmv
strain
england
respect
preliminari
data
show
rcmvencod
homolog
constitut
function
vfcgr
bigl
budt
voigt
zimmermann
unpublish
observ
mcmv
model
provid
uniqu
opportun
assess
biolog
role
vfcgr
viral
pathogenesi
immun
control
vivo
end
replic
mcmv
gene
delet
mutant
analys
mice
reveal
dramat
attenu
phenotyp
vivo
surprisingli
amt
mice
lack
ig
chain
defect
b
cell
develop
devoid
ab
viru
rescu
attenu
find
conclud
major
biolog
function
mcmv
fcgr
must
relat
igg
bind
includ
promin
iggunrel
function
known
hsv
ge
gi
howev
replac
gene
sequenc
insert
lacz
gene
escherichia
coli
might
affect
gene
neighbour
possess
common
transcript
unit
implic
macrophag
tropism
effici
mcmv
replic
vivo
furthermor
viral
replic
investig
primari
mcmv
infect
ab
contribut
viru
immun
control
therefor
avail
data
preclud
abdepend
role
mcmv
fcgr
later
phase
infect
ab
effect
limit
viru
dissemin
transmiss
studi
introduc
subtl
chang
gene
without
affect
adjac
gene
requir
elucid
put
iggdepend
function
mcmv
fcgr
recent
progress
ab
gener
technolog
allow
select
ab
perfect
specif
defin
target
structur
employ
distinct
effector
function
produc
high
quantiti
allow
therapeut
applic
patient
due
limit
convent
antivir
drug
therapi
design
potent
virusspecif
ab
therapeut
tool
demand
publish
data
support
notion
igg
import
certainli
exclus
immunolog
role
herpesvir
infect
potenti
tool
immunoprophylaxi
outlin
viral
fcgr
prime
suspect
remark
abil
hv
counteract
igg
effector
function
therefor
conceiv
assum
antivir
ab
could
reach
potent
antivir
effici
resist
fcgrmediat
attenu
accord
concept
ideal
iggfc
domain
would
bound
vfcgr
still
retain
normal
affin
ligand
recruit
protect
compon
immun
system
exampl
human
igg
ab
could
repres
promis
candid
effect
antihsv
agent
sinc
igg
subclass
potent
activ
complement
cascad
block
hsv
ge
gi
base
discrimin
hsv
ge
gi
fcgr
higg
allotyp
even
minim
mutat
introduc
recombin
ab
could
suffici
avoid
vfcgr
bind
retain
function
properti
molecul
respect
cfcgr
complement
hcmv
encod
even
two
fcgr
bind
human
igg
subclass
although
grade
affin
make
design
discrimin
iggfc
domain
complex
detail
understand
interact
cmv
fcgr
iggfc
includ
ultrastructur
analysi
would
facilit
model
effect
igg
viru
prototyp
iggfc
domain
fulfil
requir
select
interact
found
modul
could
fuse
larg
number
hcmvreactiv
iggfab
domain
cocktail
monoclon
recombin
ab
necessari
deal
interstrain
divers
major
hcmv
neutralis
epitop
present
glycoprotein
gb
gh
order
gener
wide
effect
protect
mcmv
anim
model
could
serv
optim
test
tube
gener
experiment
evid
vivo
iggfcdepend
subvers
role
vfcgr
viral
pathogenesi
natur
host
next
proof
principl
mcmvspecif
monoclon
ab
therapeut
potenti
avail
allow
assess
therapeut
benefit
mutat
vfcgrresist
iggfc
modul
varieti
infect
condit
vivo
base
knowledg
design
igg
could
lead
new
gener
immunopharmacolog
tool
effect
larg
burden
human
herpesvir
diseas
critic
read
manuscript
work
support
deutsch
forschungsgemeinschaft
sfb
european
commun
grant
